Earnings Releases

Date Headline
8/10/2023
Zymeworks Provides Corporate Update and Reports Second Quarter 2023 Financial Results
 Summary
Net loss for the first six months of 2023 decrease d by 45% as compared to the same period in 2022 Cash resources of $431.4 million as of June¬†30, 2023 expected to fund planned operations through at least the end of 2026, and potentially beyond Presented full clinical results from Phase 2b study of  Continue Reading
5/8/2023
Zymeworks Provides Corporate Update and Reports First Quarter 2023 Financial Results
 Summary
Confirmed prior guidance on 2023 operating cash burn of between $90 and $120 million and cash runway through at least 2026, and potentially beyond Net quarterly loss decreased by 66% to $24.4 million as compared to first quarter in 2022 Presented 11 posters at the American Association for Cancer  Continue Reading
3/7/2023
Zymeworks Reports Fourth Quarter and Full Year 2022 Financial Results
 Summary
2022 was a year of transformation and change: reported $412.5 million in total revenue for the year ended December 31, 2022 ; reported net income of $124.3 million ( $1.90 per fully diluted share) for 2022 compared to net loss of $211.8 million in 2021; reported $492.2 million in cash resources as  Continue Reading